Get started
Novartis AGNovartis AGNovartis AG

Novartis AG

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsIdeasDiscussionsTechnicalsForecastSeasonalsBondsETFs

NOVN chart


Full chart

NOVN upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪200.26 B‬ CHF
Dividend yield (indicated)
3.33%
Price to earnings Ratio (TTM)
17.72
Basic EPS (TTM)
5.98 CHF
Net income (FY)
‪10.52 B‬ CHF
Revenue (FY)
‪44.31 B‬ CHF
Shares float
‪1.69 B‬
Beta (1Y)
1.04

Employees


Employees (FY)
‪75.88 K‬
Change (1Y)
−174 −0.23%
Revenue / Employee (1Y)
‪583.96 K‬ CHF
Net income / Employee (1Y)
‪138.58 K‬ CHF

About Novartis AG


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Vasant Narasimhan
Website
novartis.com
Headquarters
Basel
Founded
1996
ISIN
CH0012005267
FIGI
BBG00HCYS021
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Check out other big names from the same industry as NOVN.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NOVN news



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

NOVN highest yielding bonds


NVS5894401
Novartis Capital Corp. 4.7% 18-SEP-2054
Yield to maturity
5.28%
Maturity date
Sep 18, 2054
US66989HAS7
Novartis Capital Corp. 2.75% 14-AUG-2050
Yield to maturity
5.28%
Maturity date
Aug 14, 2050
US66989HAH1
Novartis Capital Corp. 4.4% 06-MAY-2044
Yield to maturity
5.24%
Maturity date
May 6, 2044
XPND
Novartis Capital Corp. 4.0% 20-NOV-2045
Yield to maturity
5.24%
Maturity date
Nov 20, 2045
NVS3904288
Novartis Capital Corp. 3.7% 21-SEP-2042
Yield to maturity
5.12%
Maturity date
Sep 21, 2042
XPNC
Novartis Capital Corp. 3.0% 20-NOV-2025
Yield to maturity
4.64%
Maturity date
Nov 20, 2025
NVS5894400
Novartis Capital Corp. 4.2% 18-SEP-2034
Yield to maturity
4.47%
Maturity date
Sep 18, 2034
NVS5894399
Novartis Capital Corp. 4.0% 18-SEP-2031
Yield to maturity
4.10%
Maturity date
Sep 18, 2031
US66989HAR9
Novartis Capital Corp. 2.2% 14-AUG-2030
Yield to maturity
4.03%
Maturity date
Aug 14, 2030
NVS5894398
Novartis Capital Corp. 3.8% 18-SEP-2029
Yield to maturity
3.90%
Maturity date
Sep 18, 2029
NVS4950565
Novartis Capital Corp. 2.0% 14-FEB-2027
Yield to maturity
3.84%
Maturity date
Feb 14, 2027

See all NOVN bonds 

ETFs with NOVN exposure


VXUS
Vanguard Total International Stock ETF
Weight
0.64%
Market value
‪3.43 B‬
USD
VEA
Vanguard FTSE Developed Markets ETF
Weight
0.88%
Market value
‪2.17 B‬
USD
IEFA
iShares Core MSCI EAFE ETF
Weight
1.08%
Market value
‪1.69 B‬
USD
CHDVD
iShares Swiss Dividend ETF (CH)
Weight
15.06%
Market value
‪977.84 M‬
USD
EFA
iShares MSCI EAFE ETF
Weight
1.26%
Market value
‪859.73 M‬
USD
CHSPI
iShares Core SPI(R) ETF (CH)
Weight
12.41%
Market value
‪705.95 M‬
USD
SMICHA
UBS ETF (CH) - SMI ETF -CHF dis-
Weight
16.22%
Market value
‪600.24 M‬
USD
SMIA
UBS ETF (CH) - SMI ETF Units -CHF acc-
Weight
16.22%
Market value
‪600.24 M‬
USD
VGK
Vanguard FTSE Europe ETF
Weight
1.67%
Market value
‪576.58 M‬
USD
SCHF
Schwab International Equity ETF
Weight
0.99%
Market value
‪517.46 M‬
USD
VEU
Vanguard FTSE All-World ex-US Index Fund
Weight
0.71%
Market value
‪516.16 M‬
USD

Explore more ETFs 

Sparks


Curated watchlists where NOVN is featured.

See all sparks 

Frequently Asked Questions


The current price of NOVN is 105.14 CHF — it has increased by 0.55% in the past 24 hours. Watch Novartis AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SIX exchange Novartis AG stocks are traded under the ticker NOVN.
NOVN stock has risen by 7.63% compared to the previous week, the month change is a 1.83% rise, over the last year Novartis AG has showed a 7.47% increase.
We've gathered analysts' opinions on Novartis AG future price: according to them, NOVN price has a max estimate of 119.59 CHF and a min estimate of 79.81 CHF. Watch NOVN chart and read a more detailed Novartis AG stock forecast: see what analysts think of Novartis AG and suggest that you do with its stocks.
NOVN reached its all-time high on Oct 2, 2025 with the price of 105.22 CHF, and its all-time low was 34.40 CHF and was reached on Aug 11, 2011. View more price dynamics on NOVN chart.
See other stocks reaching their highest and lowest prices.
NOVN stock is 0.69% volatile and has beta coefficient of 1.04. Track Novartis AG stock price on the chart and check out the list of the most volatile stocks — is Novartis AG there?
Today Novartis AG has the market capitalization of ‪200.76 B‬, it has increased by 1.17% over the last week.
Yes, you can track Novartis AG financials in yearly and quarterly reports right on TradingView.
Novartis AG is going to release the next earnings report on Oct 28, 2025. Keep track of upcoming events with our Earnings Calendar.
NOVN earnings for the last quarter are 1.92 CHF per share, whereas the estimation was 1.87 CHF resulting in a 2.94% surprise. The estimated earnings for the next quarter are 1.79 CHF per share. See more details about Novartis AG earnings.
Novartis AG revenue for the last quarter amounts to ‪11.15 B‬ CHF, despite the estimated figure of ‪11.16 B‬ CHF. In the next quarter, revenue is expected to reach ‪11.01 B‬ CHF.
NOVN net income for the last quarter is ‪3.34 B‬ CHF, while the quarter before that showed ‪3.24 B‬ CHF of net income which accounts for 2.96% change. Track more Novartis AG financial stats to get the full picture.
Yes, NOVN dividends are paid annually. The last dividend per share was 3.50 CHF. As of today, Dividend Yield (TTM)% is 3.31%. Tracking Novartis AG dividends might help you take more informed decisions.
Novartis AG dividend yield was 3.95% in 2024, and payout ratio reached 67.17%. The year before the numbers were 3.89% and 51.36% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Oct 7, 2025, the company has ‪75.88 K‬ employees. See our rating of the largest employees — is Novartis AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novartis AG EBITDA is ‪19.95 B‬ CHF, and current EBITDA margin is 42.72%. See more stats in Novartis AG financial statements.
Like other stocks, NOVN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novartis AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Novartis AG technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Novartis AG stock shows the strong buy signal. See more of Novartis AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.